Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial
- 2015
- Journal of Nutritional Science 4
- J. Minami
- S. Kondo
- N. Yanagisawa
- T. Odamaki
- J. Xiao
- F. Abe
- S. Nakajima
- Yukie Hamamoto
- Sanae Saitoh
- T. Shimoda
- PubMed: 26090097
- DOI: 10.1017/jns.2015.5
Abstract
Accumulating evidence suggests an association between gut microbiota and the development of obesity, raising the possibility of probiotic administration as a therapeutic approach. Bifidobacterium breve B-3 was found to exhibit an anti-obesity effect on high-fat diet-induced obesity mice. In the present study, a randomised, double-blind, placebo-controlled trial was conducted to evaluate the effect of the consumption of B. breve B-3 on body compositions and blood parameters in adults with a tendency for obesity. After a 4-week run-in period, the participants were randomised to receive either placebo or a B-3 capsule (approximately 5 × 10(10) colony-forming units of B-3/d) daily for 12 weeks. A significantly lowered fat mass was observed in the B-3 group compared with the placebo group at week 12. Improvements were observed for some blood parameters related to liver functions and inflammation, such as γ-glutamyltranspeptidase and high-sensitivity C-reactive protein. Significant correlations were found between the changed values of some blood parameters and the changed fat mass in the B-3 group. These results suggest the beneficial potential of B. breve B-3 in improving metabolic disorders.
Keywords: Bifidobacterium; DIO, diet-induced obesity; HbA1c, glycated Hb; LPS, lipopolysaccharide; Metabolic syndrome; Obesity; Randomised controlled trials; hCRP, high-sensitivity C-reactive protein; γ-GTP, γ-glutamyltranspeptidase.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Bifidobacterium breve | Improved Liver Function | Beneficial | Moderate |
Bifidobacterium breve | Reduced Body Fat Mass | Beneficial | Moderate |
Bifidobacterium breve | Reduced Inflammation Levels | Beneficial | Moderate |
Bifidobacterium breve Bb-03 | Improved Liver Function (γ-glutamyltranspeptidase) | Beneficial | Small |
Bifidobacterium breve Bb-03 | Reduced Body Fat Mass | Beneficial | Moderate |
Bifidobacterium breve Bb-03 | Reduced High-Sensitivity C-Reactive Protein | Beneficial | Small |
Bifidobacterium breve BBr60 | Improved Liver Function | Beneficial | Moderate |
Bifidobacterium breve BBr60 | Reduced Body Fat Mass | Beneficial | Moderate |
Bifidobacterium breve BBr60 | Reduced Inflammation Levels | Beneficial | Moderate |
Bifidobacterium breve BR-03 | Improved Liver Function | Beneficial | Moderate |
Bifidobacterium breve BR-03 | Reduced Body Fat Mass | Beneficial | Moderate |
Bifidobacterium breve BR-03 | Reduced Inflammatory Markers | Beneficial | Small |
Bifidobacterium breve BR03 | Improved Liver Function | Beneficial | Moderate |
Bifidobacterium breve BR03 | Improved Metabolic Parameters | Beneficial | Moderate |
Bifidobacterium breve BR03 | Reduced Body Fat Mass | Beneficial | Moderate |
Bifidobacterium breve BR03 | Reduced Inflammation Levels | Beneficial | Moderate |
Bifidobacterium breve MAK40B22B | Improved Liver Function | Beneficial | Moderate |
Bifidobacterium breve MAK40B22B | Reduced Body Fat Mass | Beneficial | Moderate |
Bifidobacterium breve MAK40B22B | Reduced Inflammatory Markers | Beneficial | Small |